A Controlled Trial of High Dietary Fiber Intake on Serum Lipids

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00593632
Recruitment Status : Completed
First Posted : January 15, 2008
Last Update Posted : March 9, 2017
Attune Foods
Information provided by (Responsible Party):
Wael Jaber, The Cleveland Clinic

Brief Summary:
The study evaluates high fiber diet intake in patients with hyperlipidemia.

Condition or disease Intervention/treatment Phase
Hyperlipidemia Dietary Supplement: Uncle Sam Cereal Not Applicable

Detailed Description:
Dietary fiber intake has been shown to have modest effect in lowering cholesterol. However, most of these studies were done with 20g/daily fiber intake. Not much is known about high dietary fiber intake (30-40 g/day) and serum cholesterol. Also, there have been small studies that have shown modest decrease in oxidative stress by increasing dietary fiber intake. The goal of our study is to determine the efficacy /safety of high dietary fiber intake in raising HDL, lowering LDL, and lowering oxidative stress in patients with hyperlipidemia.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 50 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Controlled Trial of High Dietary Fiber Intake on Serum Lipids
Actual Study Start Date : January 2008
Actual Primary Completion Date : July 2011
Actual Study Completion Date : July 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Dietary Fiber
U.S. FDA Resources

Arm Intervention/treatment
Experimental: High Fiber Intake
Two 3/4 Cup servings of high fiber Uncle Sam cereal daily
Dietary Supplement: Uncle Sam Cereal
two 3/4 cup servings daily of Uncle Sam Cereal dietary instruction on high fiber diet

Primary Outcome Measures :
  1. To test whether 30-40g of daily dietary fiber increases HDL, lowers total cholesterol and LDL levels in patients at 12 weeks [ Time Frame: 12 weeks ]

Secondary Outcome Measures :
  1. To test whether Lipoprotein (a), triglyceride level, LDL: HDL ratio, fibrinogen, CRP, Urine f1 2 isoprostane and body weight will be lowered in patients after 12weeks. [ Time Frame: 12 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • All primary and secondary prevention patients aged 18 to 80 years with known or newly diagnosed isolated hypercholesteremia or combined hyperlipidemia.
  • Inclusion criteria include patients with HDL < 35 mg/dL for a man or < 45mg/dL for women irrespective of LDL level.

Exclusion Criteria:

  • Any patients with unstable angina, untreated hypothyroidism, uncontrolled diabetes, other endocrine or metabolic diseases not actively treated, acute inflammatory diseases, severe gastrointestinal diseases, chronic renal insufficiency (GFR<30), end stage renal disease, liver disease or other severe diseases such as cancer, triglyceride level greater than 600 mg/dL, pregnant females, chronic use of systemic corticosteroid, or anticoagulants.
  • Patients who were recently started or recently had their lipid lowering medications changed within the last 4 weeks will be excluded.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00593632

United States, Ohio
Cleveland Clinic
Cleveland, Ohio, United States, 44195
Sponsors and Collaborators
The Cleveland Clinic
Attune Foods
Principal Investigator: Wael A Jaber, MD The Cleveland Clinic
Principal Investigator: Leslie Cho, MD The Cleveland Clinic

Responsible Party: Wael Jaber, Principal Investigator, The Cleveland Clinic Identifier: NCT00593632     History of Changes
Other Study ID Numbers: 07-852
First Posted: January 15, 2008    Key Record Dates
Last Update Posted: March 9, 2017
Last Verified: March 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Wael Jaber, The Cleveland Clinic:
low HDL

Additional relevant MeSH terms:
Lipid Metabolism Disorders
Metabolic Diseases